CTNS mutations in patients with cystinosis
- PMID: 10571941
- DOI: 10.1002/(SICI)1098-1004(199912)14:6<454::AID-HUMU2>3.0.CO;2-H
CTNS mutations in patients with cystinosis
Abstract
Cystinosis is an autosomal recessive lysosomal storage disease caused by mutations in the gene CTNS. The CTNS gene product, cystinosin, has 367 amino acids and seven transmembrane domains and is thought to transport cystine out of lysosomes. The most common form of cystinosis, the nephropathic or infantile type, is characterized by renal failure at 10 years of age and other systemic complications. To date, 32 different CTNS mutations have been described in nephropathic cystinosis patients. Intermediate cystinosis, with later onset of renal disease, has been associated with three different CTNS mutations. Benign or nonnephropathic cystinosis, with symptoms related only to corneal crystals and photophobia, has been associated with two other CTNS mutations. In general, only certain splicing or missense mutations are associated with milder cystinosis phenotypes. Hum Mutat 14:454-458, 1999. Published 1999 Wiley-Liss, Inc.
Similar articles
-
Identification of 14 novel CTNS mutations and characterization of seven splice site mutations associated with cystinosis.Hum Mutat. 2002 Dec;20(6):439-46. doi: 10.1002/humu.10141. Hum Mutat. 2002. PMID: 12442267
-
Molecular pathogenesis of cystinosis: effect of CTNS mutations on the transport activity and subcellular localization of cystinosin.Hum Mol Genet. 2004 Jul 1;13(13):1361-71. doi: 10.1093/hmg/ddh152. Epub 2004 May 5. Hum Mol Genet. 2004. PMID: 15128704
-
[From gene to disease: cystinosis].Ned Tijdschr Geneeskd. 2004 Mar 6;148(10):476-8. Ned Tijdschr Geneeskd. 2004. PMID: 15042893 Review. Dutch.
-
Analysis of the CTNS gene in patients of German and Swiss origin with nephropathic cystinosis.Hum Mutat. 2002 Sep;20(3):237. doi: 10.1002/humu.9063. Hum Mutat. 2002. PMID: 12204010
-
Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops.Mol Genet Metab. 2000 Sep-Oct;71(1-2):100-20. doi: 10.1006/mgme.2000.3062. Mol Genet Metab. 2000. PMID: 11001803 Review.
Cited by
-
Facial features of lysosomal storage disorders.Expert Rev Endocrinol Metab. 2022 Nov;17(6):467-474. doi: 10.1080/17446651.2022.2144229. Epub 2022 Nov 16. Expert Rev Endocrinol Metab. 2022. PMID: 36384353 Free PMC article.
-
Impairment of chaperone-mediated autophagy leads to selective lysosomal degradation defects in the lysosomal storage disease cystinosis.EMBO Mol Med. 2015 Feb;7(2):158-74. doi: 10.15252/emmm.201404223. EMBO Mol Med. 2015. PMID: 25586965 Free PMC article.
-
Cysteamine, the molecule used to treat cystinosis, potentiates the antimalarial efficacy of artemisinin.Antimicrob Agents Chemother. 2010 Aug;54(8):3262-70. doi: 10.1128/AAC.01719-09. Epub 2010 May 17. Antimicrob Agents Chemother. 2010. PMID: 20479197 Free PMC article.
-
Exacerbating and reversing lysosomal storage diseases: from yeast to humans.Microb Cell. 2017 Aug 25;4(9):278-293. doi: 10.15698/mic2017.09.588. Microb Cell. 2017. PMID: 28913343 Free PMC article. Review.
-
Cysteamine, the natural metabolite of pantetheinase, shows specific activity against Plasmodium.Exp Parasitol. 2010 Aug;125(4):315-24. doi: 10.1016/j.exppara.2010.02.009. Epub 2010 Feb 26. Exp Parasitol. 2010. PMID: 20219464 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases